Fractional Carbon dioxide LASER with Topical Methotrexate Vs Topical PUVASOL in Treatment of Vitiligo
Phase 2
Recruiting
- Conditions
- Vitiligo.Vitiligo
- Registration Number
- IRCT20230816059168N2
- Lead Sponsor
- ational University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patients willing to participate in the study
Patients of age group 10 -70 years.
Vitiligo involving less than or equal to 10% body surface area.
Exclusion Criteria
Patients using or have used other treatments for vitiligo in the recent past
Pregnant women or lactating women
Patients with segmental vitiligo
Patients on immunosuppressant medications due to other diseases
Patients having connective tissue diseases, epilepsy or photosensitivity disorders
Patient having previous radiotherapy or phototherapy.
Patients with personal or family history of melanoma and non-melanoma skin cancers
Patients having contraindications to methotrexate or PUVASOL therapy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical improvement. Timepoint: At the end of 1st and 2nd month. Method of measurement: A blinded independent medical observer will perform clinical assessments using the following grading scale for all 30 patients: 1, < 25% minimal re-pigmentation; 2, 26–50% mild re-pigmentation; 3, 51–75% moderate re-pigmentation; 4, >75% excellent re-pigmentation.;Patient satisfaction. Timepoint: At the end of 1st and 2nd month. Method of measurement: Patient satisfaction will also be assessed by grading scale i.e. 1. Unsatisfied, 2. Partially satisfied, 3. Completely satisfied.
- Secondary Outcome Measures
Name Time Method